The dual GLP-1 and glucagon receptor co-agonist mazdutide is a promising therapeutic option for type 2 diabetes (T2D) treatment, providing clinically meaningful glycaemic control and weight reduction in Chinese adults with T2D.
- Dalong Zhu
- Jiajun Zhao
- Lei Qian